Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial

Abstract

The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active treatment versus those on placebo for approximately 30 months (24-35 months) before receiving GA during a six-year organized, prospective open label study. Entry required two relapses in the previous two years and an Expanded Disability Status Scale (EDSS) score of 0-5. Patients (251) were equally randomized to daily subcutaneous G A, 20 mg, or to placebo. A fter approximately 30 months, 208 patients continued in an open label study: 101 continued on G A and 107 switched from placebo to active drug. Groups were well matched at randomization and entry to the open label study. Patients always on G A showed a steady decline in relapses: a mean of 1.5 per year at entry, a mean of 0.42 over the entire six years (95% C I=0.34-0.51), a 72% reductio n (P =0.0001). They averaged a relapse every four+ years (yearly rate 0.23 in year six) and 26/101 remain relapse free. Patients did less well if on placebo for 30 months, but relapses then declined, and by year six the rates were similar. O f patients always on GA, 69% showed neurological improvement of > 1 EDSS steps or remained stable compared with 57% if G A treatment was delayed. O f relapse-free patients always on G A over six years, only three of 26 (11%) were worse by]-1 EDSS steps, whereas nine of 21 (43%) in the placebo/active group were worse (P B-0.03). Disability, measured every six months, showed that the group of patients always on G A was relatively stable over the six years, while the group who received placebo for the first two-and-a-half years did significantly less well. Daily injections of GA were well tolerated. This longest ever organized MS treatment trial shows that delaying therapy with GA increases the risk of neurologic disability, reinforcing the rationale for using G A as a first-line treatment early in the course of relapsing-remitting MS.

Keywords

glatiramer acetate multiple sclerosis relapsing-remitting

Get full access to this article

View all access options for this article.

References

Noseworthy JH , O’Brien P , Erickson BJ , Lee D , Sneve D , Ebers GC et al. The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis . Neurology 1998; 51: 1342-1352 .

van den Noort S , Eidelman B , Miller A , Rammohan K , Holland N , Murray TJ et al. National Multiple Sclerosis Society (NMSS): disease management consensus statement. New York: National MS Society , 1998.

Oger J , Freedman M. Consensus statement of the Canadian MS Clinics Network on: the use of disease modifying agents in multiple sclerosis . Can J Neurol Sci 1999; 26: 274-275 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing -remitting multiple sclerosis: results of a phase III multicenter, double blind, placebo-controlled trial . Neurology 1995; 45: 1268-1276 .

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability . Neurology 1998; 50: 701-708 .

Wolinsky JS , Ponnada AN , Johnson KP , the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center . United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates . Mult Scler 2001; 7: 33-41 .

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Johnson KP , Brooks BR , Ford CC , Goldman A , Guarnaccia J , Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years . Mult Scler 2000; 6: 255-266 .

Comi G , Filippi M , Wolinsky JS , the European/Canadian Glatiramer Acetate Study Group . European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol 2001; 49: 290-297 .

10.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . Interferon beta- 1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial . Neurology 1995; 45: 1277-1285 .

11.

Freedman MS , the PRISMS Study Group . PRISMS 4 year results: evidence of clinical dose effect of interferon beta 1a in relapsing MS . Neurology 2000; 54: 2351-2351 .

12.

Kappos L , Clanet M. Sustained efficacy of interferon beta-1a in relapsing multiple sclerosis: 4-year results from the European dose-comparison study . 54th Annual Meeting of the American Academy of Neurology, Denver, Colorado, 13 -20 April, 2002. Poster #P06.085.

13.

Filippi M , Rovaris M , Rocca MA , Sormani MP , Wolinsky JS , Comi G et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into ‘black holes’ . Neurology 2001; 57: 731-733 .

14.

Gran B , Tranquill LR , Chen M , Bielekova B , Zhou W , Dhib-Jalbut S , Martin R. Mechanisms of immunomodulation by glatiramer acetate . Neurology 2000; 55: 1704-1714 .

15.

Neuhaus O , Farina C , Wekerle H , Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis . Neurology 2001; 56: 702-708 .

16.

Chen M , Gran B , Costello K , Johnson KP , Martin R , Dhib-Jalbut S et al. Glatiramer acetate induces a Th-2 biased response and cross reactivity with myelin basic protein in patients with MS . Mult Scler 2001; 7: 209-219 .

17.

Chen M , Conway K , Johnson KP , Martin R , Dhib-Jalbut S. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years . J Neurol Sci 2002; 201: 71-77 .